SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

Proteasome inhibition is a highly effective treatment for multiple myeloma (MM). However, virtually all patients develop proteasome inhibitor resistance, which is associated with a poor prognosis. Hyperactive small ubiquitin-like modifier (SUMO) signaling is involved in both cancer pathogenesis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Heynen, Guus J. J. E., Baumgartner, Francis, Heider, Michael, Patra, Upayan, Holz, Maximilian, Braune, Jan, Kaiser, Melanie, Schäffer, Isabell, Bamopoulos, Stefanos A., Ramberger, Evelyn, Murgai, Arunima, Ng, Yuen Lam Dora, Demel, Uta Margareta, Laue, Dominik, Liebig, Sven, Krüger, Josefine, Janz, Martin, Nogai, Axel, Schick, Markus, Mertins, Philipp, Müller, Stefan, Bassermann, Florian, Krönke, Jan, Keller, Ulrich, Wirth, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979771/
https://www.ncbi.nlm.nih.gov/pubmed/35917568
http://dx.doi.org/10.1182/bloodadvances.2022007875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979771/
https://www.ncbi.nlm.nih.gov/pubmed/35917568
http://dx.doi.org/10.1182/bloodadvances.2022007875

Ejemplares similares